Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Core Insights - Cidara Therapeutics reported financial results for Q3 2025 and provided updates on its CD388 program, which is in Phase 3 development as a potential universal preventative for influenza [1][2][4] Financial Performance - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and available-for-sale investments totaling $476.5 million, a significant increase from $196.2 million as of December 31, 2024 [7][17] - Collaboration revenue was zero for Q3 2025 and the nine months ended September 30, 2025, compared to $1.3 million for the same periods in 2024 [7] - The net loss for Q3 2025 was $83.2 million, compared to a net loss of $16.0 million for Q3 2024 [8][15] CD388 Development Updates - The Phase 3 ANCHOR study for CD388 is over 50% enrolled, with a target of 6,000 participants expected to be reached by December 2025 [2][5] - The study population has been expanded to include healthy adults over 65 years old, increasing the potential eligible population from approximately 50 million to over 100 million in the U.S. [5] - The FDA granted Breakthrough Therapy designation to CD388, which is intended to expedite the review process for therapies that show substantial improvement over existing options [5][11] Corporate Highlights - Cidara received a BARDA award valued at up to $339.2 million to support the manufacturing and clinical development of CD388 [4][5] - The company initiated the ANCHOR study in September 2025, which includes an interim analysis planned for Q1 2026 [5][6] - Presentations highlighting CD388 were made at various medical conferences, showcasing positive results from the Phase 2b NAVIGATE study [6]